With Telemedicine, Hospitals May Have More Flexible Access To 340B Drug Discounts
Executive Summary
But should a patient with little connection to a 340B covered entity other than through a telehealth visit be considered eligible for a discounted drug under the program?
You may also be interested in...
PhRMA Starts New Year With Familiar Drug Pricing Proposals Targeting The Supply Chain
Hoping to revive interest in rebate reform, PhRMA releases study saying manufacturers retain a shrinking portion of gross branded drug revenues as products move through the supply chain. The pricing distortion underscores the importance of targeting practices by payers and hospitals, the trade group argues.
340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again
Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.